S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)

Avanos Medical - AVNS Stock Forecast, Price & News

$31.16
-0.24 (-0.76%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$31.04
$31.49
50-Day Range
$25.97
$31.75
52-Week Range
$19.32
$35.91
Volume
176,817 shs
Average Volume
228,920 shs
Market Capitalization
$1.45 billion
P/E Ratio
34.62
Dividend Yield
N/A
Price Target
$29.33

Avanos Medical MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
5.9% Downside
$29.33 Price Target
Short Interest
Bearish
1.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.62mentions of Avanos Medical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.89%
From $1.52 to $1.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

833rd out of 1,026 stocks

Surgical Appliances & Supplies Industry

19th out of 23 stocks

AVNS stock logo

About Avanos Medical (NYSE:AVNS) Stock

Avanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm's portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

AVNS Stock News Headlines

AVNS Avanos Medical, Inc.
Free Stock Analysis Report: See the Right Way to Analyze Stocks
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. pixel
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
Avanos Medical, Inc. Announces Third Quarter 2022 Results
Avanos Medical (AVNS) Tops Q3 Earnings Estimates
Expert Ratings for Avanos Medical
Avanos Medical Enters Oversold Territory (AVNS)
See More Headlines
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

AVNS Company Calendar

Last Earnings
11/02/2021
Today
2/08/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
4,555
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.33
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
-5.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$5.20 million
Pretax Margin
8.15%

Debt

Sales & Book Value

Annual Sales
$744.60 million
Cash Flow
$1.96 per share
Book Value
$26.23 per share

Miscellaneous

Free Float
45,531,000
Market Cap
$1.45 billion
Optionable
Optionable
Beta
0.90

Key Executives

  • Joseph F. Woody
    Chief Executive Officer & Executive Director
  • Michael C. Greiner
    SVP, Chief Financial & Transformation Officer
  • Lee Burnes
    Senior VP-Global Research & Development
  • Michelle Scharfenberg
    Senior VP, Chief Ethics & Compliance Officer
  • William D. Haydon
    Senior VP & General Manager-Pain Franchise













AVNS Stock - Frequently Asked Questions

Should I buy or sell Avanos Medical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings
or view top-rated stocks.

What is Avanos Medical's stock price forecast for 2023?

2 brokers have issued twelve-month target prices for Avanos Medical's shares. Their AVNS share price forecasts range from $26.00 to $34.00. On average, they predict the company's stock price to reach $29.33 in the next twelve months. This suggests that the stock has a possible downside of 6.4%.
View analysts price targets for AVNS
or view top-rated stocks among Wall Street analysts.

How have AVNS shares performed in 2023?

Avanos Medical's stock was trading at $27.06 at the beginning of the year. Since then, AVNS stock has increased by 15.8% and is now trading at $31.34.
View the best growth stocks for 2023 here
.

Are investors shorting Avanos Medical?

Avanos Medical saw a increase in short interest in December. As of December 30th, there was short interest totaling 863,600 shares, an increase of 19.2% from the December 15th total of 724,600 shares. Based on an average daily volume of 224,100 shares, the short-interest ratio is presently 3.9 days. Currently, 1.9% of the shares of the stock are short sold.
View Avanos Medical's Short Interest
.

When is Avanos Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our AVNS earnings forecast
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.27 by $0.02. The firm had revenue of $184.10 million for the quarter, compared to analysts' expectations of $183.90 million. Avanos Medical had a net margin of 5.39% and a trailing twelve-month return on equity of 5.74%. During the same period last year, the business posted $0.21 EPS.

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (1.19%), Heartland Advisors Inc. (0.93%), Pacer Advisors Inc. (0.51%), New York State Teachers Retirement System (0.19%), Thrivent Financial for Lutherans (0.17%) and New York State Common Retirement Fund (0.12%). Insiders that own company stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends
.

How do I buy shares of Avanos Medical?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $31.34.

How much money does Avanos Medical make?

Avanos Medical (NYSE:AVNS) has a market capitalization of $1.46 billion and generates $744.60 million in revenue each year. The company earns $5.20 million in net income (profit) each year or $0.90 on an earnings per share basis.

How many employees does Avanos Medical have?

The company employs 4,555 workers across the globe.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.

This page (NYSE:AVNS) was last updated on 2/8/2023 by MarketBeat.com Staff